Abstract
Albumin polymeric Nanoparticles (NPs) have opened a great expectancy as for controlled drug delivery due to their therapeutic potency. Concomitantly biodegradable NPs technologies with target linked structures to pave the way of personalised medicine are becoming increasingly important in sight of a therapeutically effective research technology. This is particularly attractive for nanoparticle-based cancer delivery systems, based on the known limitations and efforts to overcome. This new group of gamma irradiated-NPs inherited both the protein delivery properties and robustness of polymer forming structures, and gamma irradiation techniques that leave clean, innocuous and biodegradable NPs.
These protein NPs made of serum albumin are referred to SA NPs that possesses several characteristics making them especially attractive to be considered as a drug delivery system. This review focused on methodologies actually being used in the synthesis and characterisation of albumin NPs and different author’s opinions on strategic ways to treat cancerous cell-lines with NPs. Utterly, challenges being overthrown by researchers are brought up to anneal an effective, all in one targeted albumin NPs to passed through in vitro and preclinical trials.
Keywords: Albumin, NPs, radiation-induced crosslinking, cancer cell-lines, therapeutic-drugs, desolvation.
Current Pharmaceutical Design
Title:Albumin Nanocarriers, γ - Irradiated Crosslinked, Combined with Therapeutic Drugs for Cancer Therapy
Volume: 23 Issue: 35
Author(s): Macarena Siri, Estefania Achilli, Mariano Grasselli and Silvia del V. Alonso*
Affiliation:
- Laboratorio de Biomembranas (LBM), Universidad Nacional de Quilmes. GBEyB, IMBICE-CONICET. Buenos Aires,Argentina
Keywords: Albumin, NPs, radiation-induced crosslinking, cancer cell-lines, therapeutic-drugs, desolvation.
Abstract: Albumin polymeric Nanoparticles (NPs) have opened a great expectancy as for controlled drug delivery due to their therapeutic potency. Concomitantly biodegradable NPs technologies with target linked structures to pave the way of personalised medicine are becoming increasingly important in sight of a therapeutically effective research technology. This is particularly attractive for nanoparticle-based cancer delivery systems, based on the known limitations and efforts to overcome. This new group of gamma irradiated-NPs inherited both the protein delivery properties and robustness of polymer forming structures, and gamma irradiation techniques that leave clean, innocuous and biodegradable NPs.
These protein NPs made of serum albumin are referred to SA NPs that possesses several characteristics making them especially attractive to be considered as a drug delivery system. This review focused on methodologies actually being used in the synthesis and characterisation of albumin NPs and different author’s opinions on strategic ways to treat cancerous cell-lines with NPs. Utterly, challenges being overthrown by researchers are brought up to anneal an effective, all in one targeted albumin NPs to passed through in vitro and preclinical trials.
Export Options
About this article
Cite this article as:
Siri Macarena , Achilli Estefania , Grasselli Mariano and del V. Alonso Silvia *, Albumin Nanocarriers, γ - Irradiated Crosslinked, Combined with Therapeutic Drugs for Cancer Therapy, Current Pharmaceutical Design 2017; 23 (35) . https://dx.doi.org/10.2174/1381612823666170615105909
DOI https://dx.doi.org/10.2174/1381612823666170615105909 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Vascularization of Biomaterials for Bone Tissue Engineering: Current Approaches and Major Challenges
Current Angiogenesis (Discontinued) Degradation of Androgen Receptor through Small Molecules for Prostate Cancer
Current Cancer Drug Targets MicroRNA Dysregulation in the Myelodysplastic Syndromes
MicroRNA Anionic Antimicrobial Peptides from Eukaryotic Organisms
Current Protein & Peptide Science Disposition of Pharmacologically Active Dietary Isoflavones in Biological Systems
Current Drug Metabolism Strategic Combination Therapies for Ovarian Cancer
Current Cancer Drug Targets Is Glyburide Safe in Pregnancy?
Current Pharmaceutical Biotechnology Nanostructured Systems in Advanced Drug Targeting for the Cancer Treatment: Recent Patents
Recent Patents on Anti-Cancer Drug Discovery Review on Patents for Ubiquitin-Proteasome Inhibitor as Medical Advance in Major Human Diseases
Recent Patents on Biomedical Engineering (Discontinued) Recent Advances in Medicinal Chemistry of Sulfonamides. Rational Design as Anti-Tumoral, Anti-Bacterial and Anti-Inflammatory Agents
Mini-Reviews in Medicinal Chemistry A Review on Subcutaneous Veins Localization Using Imaging Techniques
Current Medical Imaging Clinical and Translational Challenges in Thyroid Cancer
Current Medicinal Chemistry Synthesis and In Vitro Evaluation of Tetrahydroquinoline Derivatives as Antiproliferative Compounds of Breast Cancer via Targeting the GPER
Anti-Cancer Agents in Medicinal Chemistry Multifunctional Superparamagnetic Nanoparticles: From Synthesis to siRNA Delivery
Current Pharmaceutical Design Is Type D Personality Here to Stay? Emerging Evidence Across Cardiovascular Disease Patient Groups
Current Cardiology Reviews Antitumor Activity of Novel Benzensulfonamide Derivatives in View of their Physiochemical Properties Searched by Principal Component Analysis
Medicinal Chemistry PERK-opathies: An Endoplasmic Reticulum Stress Mechanism Underlying Neurodegeneration
Current Alzheimer Research Editorial [Hot topic:Food Addiction & Obesity Treatment Development (Executive Guest Editors: Mark S. Gold and Noni A. Graham)]
Current Pharmaceutical Design Comparison of the Structure and Biological Activities of Wild-type and Mutant Liver-targeting Peptide Modified Recombinant Human Endostatin (rES-CSP) in Human Hepatocellular Carcinoma HepG2 Cells
Protein & Peptide Letters Rational Identification of Hsp90 Inhibitors as Anticancer Lead Molecules by Structure Based Drug Designing Approach
Anti-Cancer Agents in Medicinal Chemistry